Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 11/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1789401 | 0.81 | MLNR (0.74) | MLNRCYP2D6HTR2CHTR2BPNMT | |
| SCHEMBL7855779 | 0.79 | MLNR (0.63) | MLNRCYP2D6HTR2CHTR2BPNMT | |
| SCHEMBL15812115 | 0.76 | HTR2C (0.65) | SMN1; SMN2MAPTGFERHTR2CHTR2B | |
| SCHEMBL5871440 | 0.75 | SMN1; SMN2 (0.51) | MLNRSMN1; SMN2GFERHTR2CHTR2B | |
| SCHEMBL15812065 | 0.75 | PARP11 (0.59) | CYP2D6SMN1; SMN2HTR2CHTR2BPARP11 | |
| SCHEMBL21573192 | 0.75 | PARP11 (0.44) | SMN1; SMN2HTR2CHTR2BPARP11 | |
| SCHEMBL13369061 | 0.73 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTGFERPARP11 | |
| SCHEMBL12608373 | 0.71 | HRH3 (0.51) | MLNRCYP2D6MAPTHTR2CHTR6 | |
| SCHEMBL9328756 | 0.71 | KDM4E (0.45) | SMN1; SMN2MAPTGFERTSHRHSD17B10 | |
| SCHEMBL12651580 | 0.70 | MLNR (0.50) | MLNRCYP2D6SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086701-A1 | ENANTIOSELECTIVE SYNTHESIS OF PYRROLOINDOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086701-A1 | ENANTIOSELECTIVE SYNTHESIS OF PYRROLOINDOLE COMPOUNDS | PCNA, POLR2E, POLL | MLNR 4108/4885CYP2D6 258/4885SMN1; SMN2 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.